The Economic Burden of Bronchiectasis on Patients and the Health System

"The Economic Burden of Bronchiectasis on Patients and the Health System" confronts the true financial weight bronchiectasis places on patients, families, and the broader health system.

Dr. Swenson argues bluntly that payers do not yet grasp the true economic cost of bronchiectasis, largely because the country still lacks an accurate picture of the disease's real prevalence. As epidemiological estimates improve, he says, healthcare systems will be able to arrive at a much clearer accounting of utilization and economic burden going forward. He traces how far those estimates have already shifted: a 2001 study placed the annual U.S. cost at roughly $600 million, while more recent analyses put the aggregate national burden at nearly $15 billion annually. Per-patient costs vary considerably depending on disease severity, he notes, but the overall trajectory is climbing sharply year over year.

The main cost drivers, Dr. Swenson explains, are hospitalizations, unscheduled office and emergency department visits, and home intravenous antibiotic courses, all of which are expensive for patients, their households, and the health system broadly. He expects that financial impact to keep growing as the true scope of bronchiectasis becomes more widely recognized among clinicians, hospital systems, and payers alike. Dr. Swenson frames this rising cost curve as an opportunity rather than only a warning sign. Because hospitalization, ED visits, and home IV antibiotics are measurable outcomes, he explains, they give the field a clear target for intervention. If clinicians can act further upstream to prevent severe exacerbations before they escalate to that level of care, he argues, they have a genuine chance to bend both the clinical and financial trajectory of the disease, benefiting patients, families, and payers alike over the years ahead.

In "Reducing Bronchiectasis Mortality: Treatment Advances and What's Next," Dr. Swenson closes out this conversation with a look at what has moved the needle on bronchiectasis mortality and where the field goes next.